Allergen reference doses for precautionary labeling (VITAL 2.0): clinical implications.

Area of Science:

• Food science and allergy research
• Toxicology and risk assessment
• Public health and nutrition

Background:

• Widespread precautionary allergen labeling limits safe food choices for allergic consumers.
• Manufacturers use labeling to mitigate perceived risks from low-level allergen contamination.

Purpose of the Study:

• Establish reference doses for 11 common allergenic foods.
• Guide manufacturers toward a rational approach for allergen labeling.
• Utilize all available valid oral food challenge data.

Main Methods:

• Developed reference doses using statistical dose-distribution modeling.
• Analyzed individual thresholds from over 55 oral food challenge studies.
• Assessed data representativeness for peanut, milk, egg, and hazelnut.

Main Results:

• Study methodology heterogeneity and age had minimal impact on results for peanut and hazelnut.
• Eliciting dose for 1% of the allergic population: 0.2 mg protein for peanut, 0.1 mg for cow's milk, 0.03 mg for egg, 0.1 mg for hazelnut.
• Established reference doses for four key allergens based on clinical data.

Conclusions:

• Reference doses will inform the revised Voluntary Incidental Trace Allergen Labeling (VITAL) 2.0 thresholds in Australia.
• New thresholds will enable credible precautionary labeling by manufacturers.
• Improved labeling enhances consumer confidence, validity, reliability, and safety.